STOCK TITAN

Rhythm Pharmaceuticals director sells 10,000 shares

Available on EDGAR Accepted by SEC EDGAR Learn about SEC filing dates
(Neutral)

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

Form Type
4

Rhea-AI Filing Summary

Rhythm Pharmaceuticals, Inc. director Christophe Jean exercised options for 10,000 shares at an exercise price of $34.89 per share and acquired 10,000 common shares on November 17, 2026. He also sold 5,000 shares at $106.81 per share, 2,500 at $110.00 and 2,500 at $115.00. The exercise and sales were effected pursuant to a Rule 10b5-1 trading plan adopted August 18, 2026.

Insider JEAN CHRISTOPHE
Role Director
Sold 10,000 shs ($1.10M)
Approx. gross sale proceeds $1.10M
Approx. exercise cost $349K
Approx. pre-tax spread $748K
Type Security Shares Price Value
Exercise Stock Options (Right to Buy) F1, F2 10,000 $0.00 $0.00
Exercise Common Stock F1 10,000 $34.89 $349K
Sale Common Stock F1 5,000 $106.81 $534K
Sale Common Stock F1 2,500 $110.00 $275K
Sale Common Stock F1 2,500 $115.00 $288K
Holdings After Transaction: Stock Options (Right to Buy) — 0 options (Direct); Common Stock — 11,712 shares (Direct)
Footnotes (2)
  1. F1. The exercise and sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 18, 2026.
  2. F2. The options fully vested upon the earlier of (i) 1 year from the date of grant or (ii) the date of the Issuer's next annual meeting of the stockholders.
Options exercised 10,000 shares November 17, 2026
Exercise price $34.89 per share Options exercised November 17, 2026
Common shares acquired 10,000 shares November 17, 2026
Sale transaction 5,000 shares at $106.81 per share November 17, 2026
Sale transaction 2,500 shares at $110.00 per share November 17, 2026
Sale transaction 2,500 shares at $115.00 per share November 17, 2026
Rule 10b5-1 trading plan regulatory
"effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person"
A Rule 10b5-1 trading plan is a pre-arranged schedule that allows company insiders to buy or sell stock at specific times, even if they have inside information. It helps prevent accusations of unfair trading by making these transactions look planned and transparent, rather than sneaky or illegal.
fully vested financial
"options fully vested upon the earlier of"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

How many RYTM shares did director Christophe Jean sell?

Christophe Jean sold 10,000 shares on November 17, 2026: 5,000 at $106.81 per share, 2,500 at $110.00 and 2,500 at $115.00. The sales were effected pursuant to a Rule 10b5-1 trading plan adopted August 18, 2026.

What was the vesting condition for the options exercised by RYTM director Christophe Jean?

The options fully vested upon the earlier of one year from the grant date or the date of Rhythm Pharmaceuticals' next annual meeting of stockholders.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
SEC Form 4
FORM 4UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number:3235-0287
Estimated average burden
hours per response:0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
X
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
JEAN CHRISTOPHE

(Last)(First)(Middle)
C/O RHYTHM PHARMACEUTICALS, INC.
222 BERKELEY STREET, 12TH FLOOR

(Street)
BOSTON MASSACHUSETTS 02116

(City)(State)(Zip)

UNITED STATES

(Country)
2. Issuer Name and Ticker or Trading Symbol
RHYTHM PHARMACEUTICALS, INC. [ RYTM ]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
XDirector10% Owner
Officer (give title below)Other (specify below)
2a. Foreign Trading Symbol
3. Date of Earliest Transaction (Month/Day/Year)
11/17/2026
6. Individual or Joint/Group Filing (Check Applicable Line)
XForm filed by One Reporting Person
Form filed by More than One Reporting Person
4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year)2A. Deemed Execution Date, if any (Month/Day/Year)3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeVAmount(A) or (D)Price
Common Stock11/17/2026M(1)10,000A$34.8921,712D
Common Stock11/17/2026S(1)5,000D$106.8116,712D
Common Stock11/17/2026S(1)2,500D$11014,212D
Common Stock11/17/2026S(1)2,500D$11511,712D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year)3A. Deemed Execution Date, if any (Month/Day/Year)4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year)7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeV(A)(D)Date ExercisableExpiration DateTitleAmount or Number of Shares
Stock Options (Right to Buy)$34.8911/17/2026M(1)10,000 (2)06/05/2028Common Stock10,000$00D
Explanation of Responses:
1. The exercise and sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 18, 2026.
2. The options fully vested upon the earlier of (i) 1 year from the date of grant or (ii) the date of the Issuer's next annual meeting of the stockholders.
/s/ Stephen Vander Stoep, attorney-in-fact for Christophe Jean11/18/2026
** Signature of Reporting PersonDate
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Keep reading